Alternatively, CRISPR-Cas9 knock-out of NKG2A in NK cells has been demonstrated to improve anticancer activity of anti-CD33-CAR-NK cells against AML both in vitro and in vivo [47] and this could be applied to improve CAR-NK cell function within the lymph node microenvironment of B cell malignancies. This evidence concerns the gene CD33 and acute myeloid leukemia.